AI assistant
Sending…
FENNEC PHARMACEUTICALS INC. — Director's Dealing 2007
Mar 5, 2007
35599_dirs_2007-03-05_59174e0f-2c04-4e64-b03a-514276a5a8a1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ADHEREX TECHNOLOGIES INC (AMEX:ADH)
CIK: 0001211583
Period of Report: 2007-02-21
Reporting Person: Mermelstein Fred H (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 35591 | Direct |
| Common Stock | 1327819 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to buy) | $.28 | 2014-02-28 | Common Stock (50000) | Direct | |
| Stock Options (Right to buy) | $1.2 | 2012-09-21 | Common Stock (30000) | Direct | |
| Stock Options (Right to buy) | $1.2 | 2012-05-18 | Common Stock (18621) | Direct | |
| Stock Options (Right to buy) | $1.7 | 2010-05-03 | Common Stock (7800) | Direct | |
| Stock Options (Right to buy) | $2.9 | 2011-05-21 | Common Stock (4000) | Direct | |
| Stock Options (Right to buy) | $3.25 | 2011-03-01 | Common Stock (18621) | Direct | |
| Warrants (Right to buy) | $2.15 | 2008-12-19 | Common Stock (23078) | Direct | |
| Warrants (Right to buy) | $3.585 | 2007-11-20 | Common Stock (76384) | Indirect |
Footnotes
F1: The options to which this note relates are subject to vesting in three (3) installments with one-third vesting immediately and the remaining shares vesting on the first and second anniversary of the Grant Date reported above.
F4: Exercise price for these warrants are in Canadian Dollars.
F2: The options to which this note relates vest in three (3) equal installments beginning on the date reported above.
F3: Exercise price for these options are in Canadian Dollars.
More from FENNEC PHARMACEUTICALS INC.
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 7
Annual Report
2026
Mar 27
Regulatory Filings
2026
Mar 24
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 20